(Q46090429)

19 December 2017

title

Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies (English)

1 reference

19 December 2017

1 reference

Sarapa N

1

1 reference

19 December 2017

Nickens DJ

2

1 reference

19 December 2017

Raber SR

3

1 reference

19 December 2017

Reynolds RR

4

1 reference

19 December 2017

Amantea MA

5

1 reference

19 December 2017

language of work or name

English

0 references

publication date

20 June 2007

1 reference

19 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

19 December 2017

volume

83

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

153-159

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100263

exact match

0 references

cites work

Drug-induced torsades de pointes and implications for drug development.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Drugs, QT interval prolongation and ICH E14: the need to get it right

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

A review of the cardiac systemic side-effects of antihistamines: ebastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Current status of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Pharmacokinetic enhancement of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Blockade of HERG channels by HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Clinical Implications of Enzyme Induction and Enzyme Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Long QTc and torsades de pointes in human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

QT prolongation with antimicrobial agents: understanding the significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Errors in manual measurement of QT intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

Drug-induced prolongation of the QT interval: why the regulatory concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

7 January 2021

Regulatory advice on evaluation of the proarrhythmic potential of drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

7 January 2021

Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

7 January 2021

Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

7 January 2021

Alprazolam-ritonavir interaction: implications for product labeling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

7 January 2021

Thorough QT study with recommended and supratherapeutic doses of tolterodine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100263

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100263

1 reference

19 December 2017

Dimensions Publication ID

1006815848

0 references

1 reference

19 December 2017